You are here

Intracarotid Artery Transplantation of MSCs for Ischemic Stroke

A new study from the lab of Cesar V. Borlongan (University of South Florida, Tampa, Florida, USA) studied mesenchymal stem cells (MSCs) as a means to treat ischemic stroke with the recognition that critical translational gaps in stem cell transplant dose, route, and timing after stroke exist while acknowledging the need for a solid safety profiles for MSCs. In their recent STEM CELLS Translational Medicine study, Kaneko et al. tested a human bone marrow‐derived MSC called NCS‐01 in oxygen-glucose deprivation and middle cerebral artery occlusion models, discovering the optimal dose when delivered via the intracarotid artery within three days after stroke and suggesting the secretion of bFGF and IL‐6 and filopodia formation as potential mechanisms. Given these preclinical results, the US FDA approved the intracarotid NCS‐01 transplantation in ischemic stroke patients in July 2019.